Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

Market Cap	10.03B +237.2%
Revenue (ttm)	1.54B +24.5%
Net Income	99.48M +390.1%
EPS	0.45 +430.9%
Shares Out	220.49M
PE Ratio	100.47
Forward PE	n/a
Dividend	0.05 (0.12%)
Ex-Dividend Date	Jun 25, 2025

Volume	99,201,909
Average Volume	38,881,467
Open	46.50
Previous Close	43.24
Day's Range	39.97 - 47.56
52-Week Range	11.40 - 46.73
Beta	-0.37
RSI	73.64
Earnings Date	Apr 25, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 2,404
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603538

Financial Performance

In 2024, SHA:603538's revenue was 1.37 billion, an increase of 12.85% compared to the previous year's 1.22 billion. Earnings were 66.81 million, an increase of 476.64%.